Marcus Kuehne aka Huggenberg
@MK2forU
Followers
555
Following
5K
Media
101
Statuses
1K
Dancing with the proteins, Immunology, Biotechnology, Watersports
Switzerland
Joined May 2018
$IBRX The Anktiva Long Covid trial NCT07108036 is now recruiting. https://t.co/CpgFwBAwWi
$IBRX Additional Information about Anktiva in the Long Covid INTERRUPT_LC trial. https://t.co/A7tZsFasoH
3
16
98
@PepInvestStocks @PepInvestStocks Great catch on this fresh update. This is a newly posted open-label Phase 1 trial (NCT07488884 / ResQ108B-PANC, last updated March 23-25 2026, not yet recruiting, sponsored by ImmunityBio). It tests the IL-15 therapy in the neoadjuvant (pre-surgery) setting for
0
2
5
$IBRX Related to the NANT Leonardo platform: ImmunityBio ($IBRX) and MiNK Therapeutics are expanding into the infectious disease field by combining Anktiva with agenT-797 (invariant natural killer T cell) in the NCT07492888 trial, announced today. Further details on the broader
3
7
97
$IBRX The NANT Leonardo system in brief details. What if cancer immunotherapy were built on a versatile immune platform rather than a single drug like Anktiva? I discuss how ImmunityBio’s NANT Leonardo system could begin with NK cells and progressively evolve into a comprehensive
This is how we build the 'World Bank of NK Cells' and make Immunotherapy 2.0 accessible to all of humanity. Our M-ceNK Phase 2 clinical trials ongoing with process development from over 60 healthy volunteers and patients with cancer completed to date. The future of growing
0
19
104
$IBRX BCG unresponsive NMIBC: This will benefit an additional 175,000 patients! This will quadruple the patient base in the US alone. Including the EU/UK, the patient base will grow tenfold, from 18,000 to 192,000, and it will expand further if Saudi Arabia and other countries
$IBRX new NCCN guideline! I could be wrong but, now insurance will pay for ANKTIVA instead of Chemo/Radiation. It is huge! @DrPatrick @LoriMills4CA42
7
20
120
Thank you, @DrPatrick, for your kind words. I truly value your support, especially coming from someone whose scientific articles I greatly respect, and whose presentations and patents I have followed for years. As you mentioned, I form my own conclusions and envision possible
Incredible, @MK2forU connected the dots that I have been trying for decades to do. I'm glad this comes from a scientist unrelated to @ImmunityBio and speaking about the future of cancer care. The future is here. Certain countries have recognized the opportunity and are eagerly
6
14
124
$IBRX Soon, there will be evidence confirming the accuracy of my analysis and evaluation of the Leonardo platform. https://t.co/HaSNOS8KGV
The world bank of natural killer cells is close. Data from production of billions of NK cells and successful cryopreservation from pver 60 healthy volunteers and cancer patients coming soon. The Leonardo AI driven robot will transform the availability of NK cells globally.
11
34
256
$IBRX This will reshape the competitors’ landscape: With Anktiva, the per-patient cost is $415,000 (25%) lower for Bladder Cancer (NMIBC CIS) than for TAR-200 after 15 months. Anktiva’s long-lasting, durable response rate keeps patients disease-free for over 54 months without
7
19
119
Read about ImmunityBio’s Leoardo Apheresis platform, which also features iNKT cells and the link to MiNK Therapeutics : https://t.co/HaSNOS8KGV
0
1
5
ImmunityBio $IBRX and MiNK Therapeutics $INKT are entering the infectious disease sector by combining Anktiva with agenT-797, an allogenic, off-the-shelf invariant natural killer T (iNKT) cell. A case report on this will be showcased at the American Thoracic Society (ATS)
2
8
78
$IBRX NK/iNKT cell banking via the Leonardo Apheresis platform will become scalable, and IBRX will shift from a single-drug company (Anktiva) to an immune infrastructure company capable of targeting TAM in both cancer and sepsis. https://t.co/HaSNOS8KGV
2
8
58
Most see $IBRX primarily as a cancer story, but a banked NK/iNKT platform targeting both tumors and sepsis-induced lymphopenia could serve as a versatile immune infrastructure across multiple indications. https://t.co/HaSNOS8KGV
3
13
93
$IBRX Imagine if cancer immunotherapy was more than just a drug — it could be a fully programmable immune platform. I describe how ImmunityBio’s Leonardo system begins with NK cells and progressively develops into a comprehensive immune restoration, with possible uses beyond
2
7
68
$IBRX
مؤسس شركة "ImmunityBio" للأدوية د."شيونغ": نجاح لقاء مايو 2025 مع الأمير #محمد_بن_سلمان والرئيس "ترامب" أثمر مسارًا متسارعًا يخدم المرضى والبشرية. اعتماد عالمي لعلاج سرطان الرئة، وتأسيس شركة مملوكة في السعودية لدعم المنظومة الصحية بالمنطقة، مع جاهزية توزيع "Anktiva" لمرضى
0
2
16
Update: $IBRX bouncing from morning lows (~$7.73) — back to ~$8.60 and reclaiming $8 live! Dip is BUY opportunity — buy and hold strong! If volume picks up on a push above $8.75–$8.86 (recent highs), it could test $9+ quickly on gamma tail + short pain. Today is Feb 20 expiry —
@ButOWhyO… appreciate the chart and order block breakdown, but this doesn’t hold up on a high-shorted stock like $IBRX (short interest ~40–45% of float, ~135M shares shorted). Order blocks work in normal markets, but here short squeezes, catalysts, and gamma hedging smash
0
3
20
Why did $IBRX choose to partner with Accord Health in Europe? Here's my personal perspective: Accord Health, a subsidiary of India-based generic manufacturer Intas Pharmaceuticals, will distribute Anktiva in Europe. Intas has significant ambitions in the Checkpoint Inhibitor
1
14
94
IngenOx, along with its Zabadinostat, is also showcasing at the USA-Saudi Botech Alliance. Last year, Zabadinostat was introduced as a potential Best-in-Class HDAC inhibitor at the $IBRX Investors Day. https://t.co/gwmekAM6GF
1
5
35
$IBRX This meeting is an extension of the outcomes of the U.S.-Saudi Biotech Alliance Summit held in San Francisco, enhancing pathways for scientific and investment cooperation, supporting knowledge transfer and innovation localization, and opening new horizons to strengthen
تتواصل أعمال اللقاء العلمي السعودي–الأمريكي للتقنية الحيوية هذا اليوم، بتنظيمٍ من وزارة الاستثمار بالتعاون مع الشؤون الصحية بوزارة الحرس الوطني ومركز الملك عبدالله العالمي للأبحاث الطبية (كيمارك)، وبدعم من مبادرة #استثمر_في_السعودية. هذا اللقاء يأتي امتدادًا لمخرجات قمة التحالف
0
9
55